Walgreens Health-System Pharmacy #10845, Kansas City, MO, USA.
Division of Pharmacy Practice and Administration, University of Missouri - Kansas City School of Pharmacy, Kansas City, MO, USA.
Curr Pharm Des. 2023;29(25):1967-1970. doi: 10.2174/1381612829666230816145931.
The treatment options for hepatitis C have undergone noteworthy advancements since direct-acting antivirals (DAAs) were introduced. The selection of a DAA therapy depends on the patient's genotype, treatment history, concomitant comorbidities, and concurrent medications. Pharmacists have a pivotal role in providing clarification and recommendations in selecting appropriate, individualized DAAs for patients. This commentary aims to (1) provide an overview of DAAs on the market for hepatitis C, and (2) describe the implication for the care of patients with hepatitis C in a community pharmacy. Community pharmacists can establish a workflow to recommend appropriate DAA therapy, identify drug interactions, and improve medication adherence and compliance with lab appointments.
自直接作用抗病毒药物 (DAAs) 问世以来，丙型肝炎的治疗选择取得了显著进展。DAA 治疗的选择取决于患者的基因型、治疗史、合并症和同时使用的药物。药剂师在为患者选择合适的个体化 DAA 方面发挥着关键作用，提供澄清和建议。本评论旨在：(1) 概述丙型肝炎市场上的 DAA；(2) 描述社区药房中丙型肝炎患者护理的影响。社区药剂师可以建立一个工作流程，以推荐合适的 DAA 治疗方案、识别药物相互作用，并提高药物依从性和实验室预约的遵守率。
